Patrick Vlieghe

TL;DR: This review reports on the unexpected and considerable number of peptides that are currently available as drugs and the chemical strategies that were used to bring them into the market.

TL;DR: This review article overviews in this review article the fundamental physiological properties of the blood–brain barrier (BBB), a physical and physiological barrier that filters very efficiently and selectively the entry of compounds from the blood to the brain and protects nervous tissue from harmful substances and infectious agents present in the bloodstream.

TL;DR: This paper describes the first covalent synthesis of kappa-carrageenan-3'-azido-3-deoxythymidine (AZT) conjugates, which contain a low AZT concentration, and could be of great therapeutic interest because these conjugate present improved anti-HIV activities relative to free AZT.

TL;DR: The ability of peptide 22 to efficiently and quickly cross CNS physiological barriers was demonstrated and its binding on the extracellular LDLR domain was explored from an NMR-oriented structural study and docking experiments.

TL;DR: It appears that N-protected covalent prodrugs are equipotent to AZT as inhibitor of HIV replication, while N-deprotected analogues exhibit both higher activity and selectivity against HIV-infected cells.